Advertisement
| business continuity plan pharmaceutical industry pdf: Business Continuity Management: How to Protect Your Company from Danger Michael Gallagher, 2002-01 Business continuity management (BCM) has become a hot topic in recent years and more significantly, in recent months (September 11, foot and mouth and flooding). However, BCM is not just about recovery from a disaster such one caused by fire or flood or the failure of IT systems. It can also be about the collapse of a key supplier or customer, about fraud, unethical operations and about reputation management.Recent surveys have shown that most companies still do not have business continuity plans and of those that have plans, many have never been tested or exercised. As a result, corporate governance, regulatory, insurance, audit and general business requirements are now emphasising the importance of robust risk management and BCM practices in every organisation.Today, it is vital that board members and senior executives understand the nature and scope of BCM. They need to be in a position to evaluate and enhance the status of the activity within their organizations. This briefing examines the nature of BCM and looks at its relationship with other activities such as risk management, insurance and the emergency services. |
| business continuity plan pharmaceutical industry pdf: Business Continuity Management Andrew Hiles, 2014-09-30 Discover new ideas and inspiration to build world-class Business Continuity Management from this masterwork that distills Hiles' wisdom about what works and why from 30+ years' experience in 60+ countries. First published in 1999, the new 4th Edition of Hiles' classic is the most international, comprehensive, readable exposition on the subject. It now includes: New or revised sections: New, extensive chapter on supply chain risk – including valuable advice on contract aspects. Horizon scanning of new risks. Fresh perspectives. Multilateral continuity planning. Impact of new technologies, including mobile computing, cloud computing, bring your own device, and the Internet of things. Extensive, up-to-the-minute coverage of global/country-specific standards, with detailed appendices on ISO 22301/22313 and NFPA 1600. BCP exercising and testing. Helpful discussion on issues relating to certification professional certification. New revealing case studies and vivid examples of crises and disruptions – and effective response to them. Updated action plans and roadmaps. Proven techniques to win consensus on BC strategy and planning. Hint of the future – what's next for BCM? Demonstrates step-by-step how to build and maintain a world-class BC management system and plan. Shares field-tested tools and hard-won insights about what works and why. Chapter learning objectives, case studies and real-life examples, self-examination and discussion questions, forms, checklists, charts and graphs, glossary, index. 520-page book + hundreds of pages of Downloadable Resources, including project plans, risk analysis forms, BIA spreadsheets, BC plan formats, exercise/test material, checklists, and a variety of editable models, templates, and spreadsheets. Instructional Materials coming soon including valuable educational tools, such as syllabi, test bank, slides – for use by approved adopters in college courses and professional development training. |
| business continuity plan pharmaceutical industry pdf: The Future of Risk Management Howard Kunreuther, Robert J. Meyer, Erwann O. Michel-Kerjan, 2019-07-26 Whether man-made or naturally occurring, large-scale disasters can cause fatalities and injuries, devastate property and communities, savage the environment, impose significant financial burdens on individuals and firms, and test political leadership. Moreover, global challenges such as climate change and terrorism reveal the interdependent and interconnected nature of our current moment: what occurs in one nation or geographical region is likely to have effects across the globe. Our information age creates new and more integrated forms of communication that incur risks that are difficult to evaluate, let alone anticipate. All of this makes clear that innovative approaches to assessing and managing risk are urgently required. When catastrophic risk management was in its inception thirty years ago, scientists and engineers would provide estimates of the probability of specific types of accidents and their potential consequences. Economists would then propose risk management policies based on those experts' estimates with little thought as to how this data would be used by interested parties. Today, however, the disciplines of finance, geography, history, insurance, marketing, political science, sociology, and the decision sciences combine scientific knowledge on risk assessment with a better appreciation for the importance of improving individual and collective decision-making processes. The essays in this volume highlight past research, recent discoveries, and open questions written by leading thinkers in risk management and behavioral sciences. The Future of Risk Management provides scholars, businesses, civil servants, and the concerned public tools for making more informed decisions and developing long-term strategies for reducing future losses from potentially catastrophic events. Contributors: Mona Ahmadiani, Joshua D. Baker, W. J. Wouter Botzen, Cary Coglianese, Gregory Colson, Jeffrey Czajkowski, Nate Dieckmann, Robin Dillon, Baruch Fischhoff, Jeffrey A. Friedman, Robin Gregory, Robert W. Klein, Carolyn Kousky, Howard Kunreuther, Craig E. Landry, Barbara Mellers, Robert J. Meyer, Erwann Michel-Kerjan, Robert Muir-Wood, Mark Pauly, Lisa Robinson, Adam Rose, Paul J. H. Schoemaker, Paul Slovic, Phil Tetlock, Daniel Västfjäll, W. Kip Viscusi, Elke U. Weber, Richard Zeckhauser. |
| business continuity plan pharmaceutical industry pdf: Business Development for the Biotechnology and Pharmaceutical Industry Martin Austin, 2016-04-08 Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world. |
| business continuity plan pharmaceutical industry pdf: Operational Risk Management and Business Continuity Planning for Modern State Treasuries International Monetary Fund, 2011-11-09 This technical note and manual addresses the following main issues: 1. What is operational risk management and how this should be applied to treasury operations. 2. What is business continuity and disaster recovery planning and why it is important for treasury operations? 3. How to develop and implement a business continuity and disaster recovery plan using a six practical-step process and how to have it imbedded into the day-to-day operations of the treasury. 4. What is needed to activate and what are the key procedures when activating the disaster recovery plan. |
| business continuity plan pharmaceutical industry pdf: Exploring Telework as a Business Continuity Strategy , 2005 |
| business continuity plan pharmaceutical industry pdf: Corporate Crime in the Pharmaceutical Industry (Routledge Revivals) John Braithwaite, 2013-10-08 First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally. |
| business continuity plan pharmaceutical industry pdf: Pharmaceutical Manufacturing Handbook Shayne Cox Gad, 2008-03-11 This handbook features contributions from a team of expert authors representing the many disciplines within science, engineering, and technology that are involved in pharmaceutical manufacturing. They provide the information and tools you need to design, implement, operate, and troubleshoot a pharmaceutical manufacturing system. The editor, with more than thirty years' experience working with pharmaceutical and biotechnology companies, carefully reviewed all the chapters to ensure that each one is thorough, accurate, and clear. |
| business continuity plan pharmaceutical industry pdf: Future Health Scenarios Maria José Sousa, Francisco Guilherme Nunes, Generosa do Nascimento, Chinmay Chakraborty, 2023-05-15 Digital technologies is a major emerging area to invest and research in new models of health management. Future health scenarios are constituted by technologies in health and clinical decision-making systems. This book provides a unique multidisciplinary approach for exploring the potential contribution of AI and digital technologies in enabling global healthcare systems to respond to urgent twenty-first-century challenges. Deep analysis has been made regarding telemedicine using big data, deep learning, robotics, mobile and remote applications. Features: Focuses on prospective scenarios in health to predict possible futures. Addresses the urgent needs of the key population, socio-technical and health themes. Covers health innovative practices as 3D models for surgeries, big data to treat rare diseases, and AI robot for heart treatments. Explores telemedicine using big data, deep learning, robotics, mobile and remote applications. Reviews public health based on predictive analytics and disease trends. This book is aimed at researchers, professionals, and graduate students in computer science, artificial intelligence, decision support, healthcare technology management, biomedical engineering, and robotics. |
| business continuity plan pharmaceutical industry pdf: The Definitive Handbook of Business Continuity Management Andrew Hiles, 2010-11-22 With a pedigree going back over ten years, The Definitive Handbook of Business Continuity Management can rightly claim to be a classic guide to business risk management and contingency planning, with a style that makes it accessible to all business managers. Some of the original underlying principles remain the same – but much has changed. This is reflected in this radically updated third edition, with exciting and helpful new content from new and innovative contributors and new case studies bringing the book right up to the minute. This book combines over 500 years of experience from leading Business Continuity experts of many countries. It is presented in an easy-to-follow format, explaining in detail the core BC activities incorporated in BS 25999, Business Continuity Guidelines, BS 25777 IT Disaster Recovery and other standards and in the body of knowledge common to the key business continuity institutes. Contributors from America, Asia Pacific, Europe, China, India and the Middle East provide a truly global perspective, bringing their own insights and approaches to the subject, sharing best practice from the four corners of the world. We explore and summarize the latest legislation, guidelines and standards impacting BC planning and management and explain their impact. The structured format, with many revealing case studies, examples and checklists, provides a clear roadmap, simplifying and de-mystifying business continuity processes for those new to its disciplines and providing a benchmark of current best practice for those more experienced practitioners. This book makes a massive contribution to the knowledge base of BC and risk management. It is essential reading for all business continuity, risk managers and auditors: none should be without it. |
| business continuity plan pharmaceutical industry pdf: Guide for All-Hazard Emergency Operations Planning Kay C. Goss, 1998-05 Meant to aid State & local emergency managers in their efforts to develop & maintain a viable all-hazard emergency operations plan. This guide clarifies the preparedness, response, & short-term recovery planning elements that warrant inclusion in emergency operations plans. It offers the best judgment & recommendations on how to deal with the entire planning process -- from forming a planning team to writing the plan. Specific topics of discussion include: preliminary considerations, the planning process, emergency operations plan format, basic plan content, functional annex content, hazard-unique planning, & linking Federal & State operations. |
| business continuity plan pharmaceutical industry pdf: Developing and Maintaining Emergency Operations Plans United States. Federal Emergency Management Agency, 2010 Comprehensive Preparedness Guide (CPG) 101 provides guidelines on developing emergency operations plans (EOP). It promotes a common understanding of the fundamentals of risk-informed planning and decision making to help planners examine a hazard or threat and produce integrated, coordinated, and synchronized plans. The goal of CPG 101 is to make the planning process routine across all phases of emergency management and for all homeland security mission areas. This Guide helps planners at all levels of government in their efforts to develop and maintain viable all-hazards, all-threats EOPs. Accomplished properly, planning provides a methodical way to engage the whole community in thinking through the life cycle of a potential crisis, determining required capabilities, and establishing a framework for roles and responsibilities. It shapes how a community envisions and shares a desired outcome, selects effective ways to achieve it, and communicates expected results. Each jurisdiction's plans must reflect what that community will do to address its specific risks with the unique resources it has or can obtain. |
| business continuity plan pharmaceutical industry pdf: Pandemic Influenza Preparedness and Response World Health Organization, World Health Organization. Global Influenza Programme, 2009 This guidance is an update of WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics, published March 2005 (WHO/CDS/CSR/GIP/2005.5). |
| business continuity plan pharmaceutical industry pdf: Pharmaceutical Manufacturing Handbook Shayne Cox Gad, 2008-04-04 With its coverage of Food and Drug Administration regulations, international regulations, good manufacturing practices, and process analytical technology, this handbook offers complete coverage of the regulations and quality control issues that govern pharmaceutical manufacturing. In addition, the book discusses quality assurance and validation, drug stability, and contamination control, all key aspects of pharmaceutical manufacturing that are heavily influenced by regulatory guidelines. The team of expert authors offer you advice based on their own firsthand experience in all phases of pharmaceutical manufacturing. |
| business continuity plan pharmaceutical industry pdf: Global Pandemic, Technology and Business Luo Li, Carlos Espaliu Berdud, Steve Foster, Ben Stanford, 2021-12-28 This book presents an exploration of a wide range of issues in law, regulation and legal rights in the sectors of information protection, the creative economy and business activities following COVID-19. The debilitative effect of the global pandemic on information protection and creative and business activities is powerful, widespread and deeply influential, bringing a range of uncertainties to these sectors. The effects of the crisis challenge the fundamentals of the legal systems of most countries in their attempt to govern them. Written by international academics from a diversified background of law disciplines and legal systems, this book offers a global vision in exploring the wide range of legal issues caused by the COVID-19 crisis in these fields. The book is organised into three clear thematic parts: Part I looks at information protection and intellectual property rights and strategies; Part II examines contracts, cooperation and mediation in the post-COVID-19 market arena; and Part III discusses issues pertaining to corporate governance and employment rights. The book explores the unprecedented challenges posed by the pandemic crisis from a global perspective. It will provide invaluable information and guidance in this area to those in the fields of law, politics and economics whose interests are related to information, business and the creative industry, as well as providing indispensable reading to business practitioners and public servants. |
| business continuity plan pharmaceutical industry pdf: A Practical Approach to Pharmaceutical Policy Andreas Seiter, 2010-06-17 This book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for developing policies that improve access to safe, effective medicines in health systems of low- and middle-income economies. |
| business continuity plan pharmaceutical industry pdf: Business Continuity Strategies Kenneth N. Myers, 2006-09-18 Cost-efficient business contingency and continuity planning for a post-9/11 and Katrina world Disasters can happen. Contingency plans are necessary. But how detailed and expensive do your contingency and continuity plans really need to be? Employing a thoroughly practical approach, Business Continuity Strategies: Protecting Against Unplanned Disasters, Third Edition provides a proven methodology for implementing a realistic and cost-efficient business contingency program. Kenneth Myers--an internationally recognized contingency planning specialist--shows corporate leaders how to prepare a logical what if plan that would enable an organization to retain market share, service customers, and maintain cash flow if a disaster occurs. Completely updated throughout to reflect lessons learned from 9/11 and hurricanes Katrina and Wilma, Business Continuity Strategies, Third Edition helps cost-conscious senior management: * Establish a corporate contingency program policy and strategy that ensures timely completion of a plan, with minimal disruption to operations * Minimize plan development costs * Understand the importance of conducting briefings to communicate the proper mindset before the program development process begins * Save time and money by avoiding a consultant's traditional approach of extensive information-gathering that contributes little to the development of practical solutions, but much in the way of consultant fees Addressing countless hypothetical disaster scenarios doesn't make good business sense. Business Continuity Strategies, Third Edition helps companies focus on what is necessary to survive a natural catastrophe, workplace violence, or a terrorist attack. |
| business continuity plan pharmaceutical industry pdf: International Health Regulations (2005) World Health Organization, 2008-12-15 In response to the call of the 48th World Health Assembly for a substantial revision of the International Health Regulations, this new edition of the Regulations will enter into force on June 15, 2007. The purpose and scope of the Regulations are to prevent, protect against, control and provide a public health response to the international spread of disease in ways that are commensurate with and restricted to public health risks, and which avoid unnecessary interference with international traffic and trade. The Regulations also cover certificates applicable to international travel and transport, and requirements for international ports, airports and ground crossings. |
| business continuity plan pharmaceutical industry pdf: WHO guideline on country pharmaceutical pricing policies , 2020-09-29 In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products. |
| business continuity plan pharmaceutical industry pdf: Enterprise Cloud Strategy Barry Briggs, Eduardo Kassner, 2016-01-07 How do you start? How should you build a plan for cloud migration for your entire portfolio? How will your organization be affected by these changes? This book, based on real-world cloud experiences by enterprise IT teams, seeks to provide the answers to these questions. Here, you’ll see what makes the cloud so compelling to enterprises; with which applications you should start your cloud journey; how your organization will change, and how skill sets will evolve; how to measure progress; how to think about security, compliance, and business buy-in; and how to exploit the ever-growing feature set that the cloud offers to gain strategic and competitive advantage. |
| business continuity plan pharmaceutical industry pdf: Quality Assurance of Aseptic Preparation Services Alison M. Beaney, 2016 Quality Assurance of Aseptic Preparation Services Standards Handbook (also known as the Yellow Guide) provides standards for unlicensed aseptic preparation in the UK, as well as practical information to aid implementation of the standards. The handbook delivers essential standards in a practical way and in a format that will be useful for pharmacy management, staff working in aseptic preparation units and those whose role it is to audit the services. The accompanying support resources help with understanding the complexities of relevant topics including microbiology, radiopharmaceuticals, advanced therapy medicinal products, technical (quality) agreements and capacity planning. All the standards have been revised and updated for this 5th edition. The text is produced on behalf of the Royal Pharmaceutical Society (RPS) and the NHS Pharmaceutical Quality Assurance Committee. New in this edition: Replaces the 4th edition standards and forms the basis for an ongoing audit program in the NHS Many new and revised standards Greater emphasis on Pharmaceutical Quality Systems; the responsibilities of pharmacy management, Chief Pharmacists (or equivalent), has been expanded in line with developments in Good Manufacturing Practice Reformatted into 2 parts: standards and support resources. This is a new collaboration between the RPS and NHS. Since the previous edition the RPS has become the professional body for pharmacists and pharmaceutical scientists. RPS launched these standards as part of a library of professional standards and a programme of work to create standards for all areas of pharmacy. The Handbook is essential for pharmacists, hospital pharmacy management and technical services teams, and auditors of unlicensed NHS hospital pharmacy aseptic preparation services in the UK, pharmacists and regulators. The text is used to inform standards used in several other countries. |
| business continuity plan pharmaceutical industry pdf: Guide to Industrial Control Systems (ICS) Security Keith Stouffer, 2015 |
| business continuity plan pharmaceutical industry pdf: Management Information Systems Kenneth C. Laudon, Jane Price Laudon, 2004 Management Information Systems provides comprehensive and integrative coverage of essential new technologies, information system applications, and their impact on business models and managerial decision-making in an exciting and interactive manner. The twelfth edition focuses on the major changes that have been made in information technology over the past two years, and includes new opening, closing, and Interactive Session cases. |
| business continuity plan pharmaceutical industry pdf: The Resilient Enterprise Yossi Sheffi, 2007-02-23 Stories from Nokia, Dell, UPS, Toyota, and other companies show how firms can reduce their vulnerability to high-impact distributions, from earthquakes to strikes, from SARS to terrorism, and use them for competitive advantage. What happens when fire strikes the manufacturing plant of the sole supplier for the brake pressure valve used in every Toyota? When a hurricane shuts down production at a Unilever plant? When Dell and Apple chip manufacturers in Taiwan take weeks to recover from an earthquake? When the U.S. Pacific ports are shut down during the Christmas rush? When terrorists strike? In The Resilient Enterprise, Yossi Sheffi shows that companies' fortunes in the face of such business shocks depend more on choices made before the disruption than they do on actions taken in the midst of it—and that resilience benefits firms every day, disaster or no disaster. He shows how companies can build in flexibility throughout their supply chains, based on proven design principles and the right culture—balancing security, redundancy, and short-term profits. And he shows how investments in resilience and flexibility not only reduce risk but create a competitive advantage in the increasingly volatile marketplace.Sheffi describes the way companies can increase security—reducing the likelihood of a disruption—with layered defenses, the tracking and analysis of “near-misses,” fast detection, and close collaboration with government agencies, trading partners, and even competitors. But the focus of the book is on resilience—the ability to bounce back from disruptions and disasters—by building in redundancy and flexibility. For example, standardization, modular design, and collaborative relationships with suppliers (and other stakeholders) can help create a robust supply chain. And a corporate culture of flexibility—with distributed decision making and communications at all levels—can create a resilient enterprise.Sheffi provides tools for companies to reduce the vulnerability of the supply chain they live in. And along the way he tells the stories of dozens of enterprises, large and small, including Toyota, Nokia, General Motors, Zara, Land Rover, Chiquita, Aisin Seiki, Southwest Airlines, UPS, Johnson and Johnson, Intel, Amazon.com, the U.S. Navy, and others, from across the globe. Their successes, failures, preparations, and methods provide a rich set of lessons in preparing for and managing disruptions. Additional material available at www.TheResilientEnterprise.com. |
| business continuity plan pharmaceutical industry pdf: Fundamentals of Business Process Management Marlon Dumas, Marcello La Rosa, Jan Mendling, Hajo A. Reijers, 2018-03-23 This textbook covers the entire Business Process Management (BPM) lifecycle, from process identification to process monitoring, covering along the way process modelling, analysis, redesign and automation. Concepts, methods and tools from business management, computer science and industrial engineering are blended into one comprehensive and inter-disciplinary approach. The presentation is illustrated using the BPMN industry standard defined by the Object Management Group and widely endorsed by practitioners and vendors worldwide. In addition to explaining the relevant conceptual background, the book provides dozens of examples, more than 230 exercises – many with solutions – and numerous suggestions for further reading. This second edition includes extended and completely revised chapters on process identification, process discovery, qualitative process analysis, process redesign, process automation and process monitoring. A new chapter on BPM as an enterprise capability has been added, which expands the scope of the book to encompass topics such as the strategic alignment and governance of BPM initiatives. The textbook is the result of many years of combined teaching experience of the authors, both at the undergraduate and graduate levels as well as in the context of professional training. Students and professionals from both business management and computer science will benefit from the step-by-step style of the textbook and its focus on fundamental concepts and proven methods. Lecturers will appreciate the class-tested format and the additional teaching material available on the accompanying website. |
| business continuity plan pharmaceutical industry pdf: Strengthening Post-Hurricane Supply Chain Resilience National Academies of Sciences, Engineering, and Medicine, Policy and Global Affairs, Office of Special Projects, Committee on Building Adaptable and Resilient Supply Chains After Hurricanes Harvey, Irma, and Maria, 2020-04-02 Resilient supply chains are crucial to maintaining the consistent delivery of goods and services to the American people. The modern economy has made supply chains more interconnected than ever, while also expanding both their range and fragility. In the third quarter of 2017, Hurricanes Harvey, Irma and Maria revealed some significant vulnerabilities in the national and regional supply chains of Texas, Florida, the U.S. Virgin Islands, and Puerto Rico. The broad impacts and quick succession of these three hurricanes also shed light on the effectiveness of the nation's disaster logistics efforts during response through recovery. Drawing on lessons learned during the 2017 hurricanes, this report explores future strategies to improve supply chain management in disaster situations. This report makes recommendations to strengthen the roles of continuity planning, partnerships between civic leaders with small businesses, and infrastructure investment to ensure that essential supply chains will remain operational in the next major disaster. Focusing on the supply chains food, fuel, water, pharmaceutical, and medical supplies, the recommendations of this report will assist the Federal Emergency Management Agency as well as state and local officials, private sector decision makers, civic leaders, and others who can help ensure that supply chains remain robust and resilient in the face of natural disasters. |
| business continuity plan pharmaceutical industry pdf: Continuous Manufacturing for the Modernization of Pharmaceutical Production National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, 2019-04-05 On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop. |
| business continuity plan pharmaceutical industry pdf: Framework for a Public Health Emergency Operations Centre World Health Organization, 2015-12-15 The Framework for a Public Health Emergency Operations Centre (PHEOC framework) document is intended to be used by practitioners of public health; health policy makers; and authorities and agencies responsible for managing emergencies, incidents, or events where the health of populations is at risk. This document provides high-level methodical guidance for designing, developing, and strengthening of public health emergency operations centers. This interim document outlines the key concepts and essential requirements for developing and managing a public health EOC (PHEOC). The overall approach is generic and based on widely acknowledged elements of all-hazards emergency management. It provides an outline for developing and managing a PHEOC to achieve a goal-oriented response to public health emergencies and unity of effort among response agencies. The document will be revised as necessary. Practical guidance on specific aspects of the PHEOC framework will be developed and published separately. A public health emergency is here defined as an occurrence, or imminent threat, of an illness or health condition that poses a substantial risk of a significant number of human fatalities, injuries or permanent or long-term disability. Public health emergencies can result from a wide range of hazards and complex emergencies. Experience has shown that timely implementation of an EOC provides an essential platform for the effective management of public health emergencies. Public health emergencies involve increased incidence of illness, injury and/or death and require special measures to address increased morbidity, mortality and interruption of essential health services. For such emergencies, a multi-agency, multi-jurisdictional response is often required, working with the national disaster management organization. When normal resources and capacities are exceeded, support from outside the affected areas will also be required. External assistance could include national, cross-border, regional or international resources. |
| business continuity plan pharmaceutical industry pdf: Disaster Resilience National Academies, Policy and Global Affairs, Committee on Science, Engineering, and Public Policy, Committee on Increasing National Resilience to Hazards and Disasters, 2012-12-29 No person or place is immune from disasters or disaster-related losses. Infectious disease outbreaks, acts of terrorism, social unrest, or financial disasters in addition to natural hazards can all lead to large-scale consequences for the nation and its communities. Communities and the nation thus face difficult fiscal, social, cultural, and environmental choices about the best ways to ensure basic security and quality of life against hazards, deliberate attacks, and disasters. Beyond the unquantifiable costs of injury and loss of life from disasters, statistics for 2011 alone indicate economic damages from natural disasters in the United States exceeded $55 billion, with 14 events costing more than a billion dollars in damages each. One way to reduce the impacts of disasters on the nation and its communities is to invest in enhancing resilience-the ability to prepare and plan for, absorb, recover from and more successfully adapt to adverse events. Disaster Resilience: A National Imperative addresses the broad issue of increasing the nation's resilience to disasters. This book defines national resilience, describes the state of knowledge about resilience to hazards and disasters, and frames the main issues related to increasing resilience in the United States. It also provide goals, baseline conditions, or performance metrics for national resilience and outlines additional information, data, gaps, and/or obstacles that need to be addressed to increase the nation's resilience to disasters. Additionally, the book's authoring committee makes recommendations about the necessary approaches to elevate national resilience to disasters in the United States. Enhanced resilience allows better anticipation of disasters and better planning to reduce disaster losses-rather than waiting for an event to occur and paying for it afterward. Disaster Resilience confronts the topic of how to increase the nation's resilience to disasters through a vision of the characteristics of a resilient nation in the year 2030. Increasing disaster resilience is an imperative that requires the collective will of the nation and its communities. Although disasters will continue to occur, actions that move the nation from reactive approaches to disasters to a proactive stance where communities actively engage in enhancing resilience will reduce many of the broad societal and economic burdens that disasters can cause. |
| business continuity plan pharmaceutical industry pdf: A Guide to Business Continuity Planning Canada. Public Safety and Emergency Preparedness Canada, 2005 |
| business continuity plan pharmaceutical industry pdf: Creating Resilient Supply Chains Helen Peck, 2003-12-01 |
| business continuity plan pharmaceutical industry pdf: Guide to Business Planning Graham Friend, Stefan Zehle, 2009-04 A comprehensive guide to every aspect of preparing and using a business plan--newly updated and revised. New businesses and existing businesses fare better with well-thought-out plans. It is essential to have a good business plan to raise capital--either for a new venture to get additional capital or within most corporations for new initiatives or for accelerated growth--Provided by publisher. |
| business continuity plan pharmaceutical industry pdf: Logistics Management and Strategy Alan Harrison, Heather Skipworth, Remko I. van Hoek, James Aitken, 2019 |
| business continuity plan pharmaceutical industry pdf: Business Continuity and Disaster Recovery Planning for IT Professionals Susan Snedaker, 2011-04-18 Powerful Earthquake Triggers Tsunami in Pacific. Hurricane Katrina Makes Landfall in the Gulf Coast. Avalanche Buries Highway in Denver. Tornado Touches Down in Georgia. These headlines not only have caught the attention of people around the world, they have had a significant effect on IT professionals as well. As technology continues to become more integral to corporate operations at every level of the organization, the job of IT has expanded to become almost all-encompassing. These days, it's difficult to find corners of a company that technology does not touch. As a result, the need to plan for potential disruptions to technology services has increased exponentially. That is what Business Continuity Planning (BCP) is: a methodology used to create a plan for how an organization will recover after a disaster of various types. It takes into account both security and corporate risk management tatics.There is a lot of movement around this initiative in the industry: the British Standards Institute is releasing a new standard for BCP this year. Trade shows are popping up covering the topic.* Complete coverage of the 3 categories of disaster: natural hazards, human-caused hazards, and accidental and technical hazards.* Only published source of information on the new BCI standards and government requirements.* Up dated information on recovery from cyber attacks, rioting, protests, product tampering, bombs, explosions, and terrorism. |
| business continuity plan pharmaceutical industry pdf: Supply Chain Risk George A. Zsidisin, Bob Ritchie, 2008-09-08 Risk is of fundamental importance in this era of the global economy. Supply chains must into account the uncertainty of demand. Moreover, the risk of uncertain demand can cut two ways: (1) there is the risk that unexpected demand will not be met on time, and the reverse problem (2) the risk that demand is over estimated and excessive inventory costs are incurred. There are other risks in unreliable vendors, delayed shipments, natural disasters, etc. In short, there are a host of strategic, tactical and operational risks to business supply chains. Supply Chain Risk: A Handbook of Assessment, Management, and Performance will focus on how to assess, evaluate, and control these various risks. |
| business continuity plan pharmaceutical industry pdf: Making Markets for Vaccines Owen Barder, Alice Albright, Michael Kremer, Ruth Levine, 2005 A legacy of our generation -- Ch. 1. We need to invest more in vaccines -- Ch. 2. Promoting private investment in vaccine development -- Ch. 3. A market not a prize -- Ch. 4. Design choices -- Ch. 5. $3 billion per disease -- Ch. 6. Meeting industry requirements -- Ch. 7. How sponsors can do it. |
| business continuity plan pharmaceutical industry pdf: A Guide to Business Continuity Planning James C. Barnes, 2001-06-08 The interest in Business Continuity has gained significant momentum in the last few years, especially with the Y2K non-event, the increasing corporate dependence on computer systems and the growing levels of devastation associated with recent disasters. This book takes an organization interested in continuity planning through the processes needed to develop an effective plan. Jim Barnes has succeeded in providing us a much-needed tool, with which we can condidently face many of the day-to-day challenges of business contingency planning ... With this book, he has taken an important step in removing much of the guesswork and frustration from the business continuity implementation project. From the Foreword by Philip Jan Rothstein, FBCI, President of Rothstein Associates Inc., Publisher of The Rothstein Catalog on Disaster Recovery, 2001 |
| business continuity plan pharmaceutical industry pdf: Green Techniques for Organic Synthesis and Medicinal Chemistry Wei Zhang, Berkeley W. Cue, 2018-01-18 An updated overview of the rapidly developing field of green techniques for organic synthesis and medicinal chemistry Green chemistry remains a high priority in modern organic synthesis and pharmaceutical R&D, with important environmental and economic implications. This book presents comprehensive coverage of green chemistry techniques for organic and medicinal chemistry applications, summarizing the available new technologies, analyzing each technique’s features and green chemistry characteristics, and providing examples to demonstrate applications for green organic synthesis and medicinal chemistry. The extensively revised edition of Green Techniques for Organic Synthesis and Medicinal Chemistry includes 7 entirely new chapters on topics including green chemistry and innovation, green chemistry metrics, green chemistry and biological drugs, and the business case for green chemistry in the generic pharmaceutical industry. It is divided into 4 parts. The first part introduces readers to the concepts of green chemistry and green engineering, global environmental regulations, green analytical chemistry, green solvents, and green chemistry metrics. The other three sections cover green catalysis, green synthetic techniques, and green techniques and strategies in the pharmaceutical industry. Includes more than 30% new and updated material—plus seven brand new chapters Edited by highly regarded experts in the field (Berkeley Cue is one of the fathers of Green Chemistry in Pharma) with backgrounds in academia and industry Brings together a team of international authors from academia, industry, government agencies, and consultancies (including John Warner, one of the founders of the field of Green Chemistry) Green Techniques for Organic Synthesis and Medicinal Chemistry, Second Edition is an essential resource on green chemistry technologies for academic researchers, R&D professionals, and students working in organic chemistry and medicinal chemistry. |
| business continuity plan pharmaceutical industry pdf: Global Trends 2040 National Intelligence Council, 2021-03 The ongoing COVID-19 pandemic marks the most significant, singular global disruption since World War II, with health, economic, political, and security implications that will ripple for years to come. -Global Trends 2040 (2021) Global Trends 2040-A More Contested World (2021), released by the US National Intelligence Council, is the latest report in its series of reports starting in 1997 about megatrends and the world's future. This report, strongly influenced by the COVID-19 pandemic, paints a bleak picture of the future and describes a contested, fragmented and turbulent world. It specifically discusses the four main trends that will shape tomorrow's world: - Demographics-by 2040, 1.4 billion people will be added mostly in Africa and South Asia. - Economics-increased government debt and concentrated economic power will escalate problems for the poor and middleclass. - Climate-a hotter world will increase water, food, and health insecurity. - Technology-the emergence of new technologies could both solve and cause problems for human life. Students of trends, policymakers, entrepreneurs, academics, journalists and anyone eager for a glimpse into the next decades, will find this report, with colored graphs, essential reading. |
| business continuity plan pharmaceutical industry pdf: Practical Aspects of Signal Detection in Pharmacovigilance Council for International Organizations of Medical Sciences (CIOMS), 2010 In recent years public expectations for rapid identification and prompt management of emerging drug safety issues have grown swiftly. Over a similar timeframe, the move from paper-based adverse event reporting systems to electronic capture and rapid transmission of data has resulted in the accrual of substantial datasets capable of complex analysis and querying by industry, regulators and other public health organizations. These two drivers have created a fertile environment for pharmacovigilance scientists, information technologists and statistical experts, working together, to deliver novel approaches to detect signals from these extensive and quickly growing datasets, and to manage them appropriately. In following this exciting story, this report looks at the practical consequences of these developments for pharmacovigilance practitioners. The report provides a comprehensive resource for those considering how to strengthen their pharmacovigilance systems and practices, and to give practical advice. But the report does not specify instant solutions. These will inevitably be situation specific and require careful consideration taking into account local needs. However, the CIOMS Working Group VIII is convinced that the combination of methods and a clear policy on the management of signals will strengthen current systems. Finally, in looking ahead, the report anticipates a number of ongoing developments, including techniques with wider applicability to other data forms than individual case reports. The ultimate test for pharmacovigilance systems is the demonstration of public health benefit and it is this test which signal detection methodologies need to meet if the expectations of all stakeholders are to be fulfilled. |
BUSINESS | English meaning - Cambridge Dictionary
BUSINESS definition: 1. the activity of buying and selling goods and services: 2. a particular company that buys and….
VENTURE | English meaning - Cambridge Dictionary
VENTURE definition: 1. a new activity, usually in business, that involves risk or uncertainty: 2. to risk going….
ENTERPRISE | English meaning - Cambridge Dictionary
ENTERPRISE definition: 1. an organization, especially a business, or a difficult and important plan, especially one that….
INCUMBENT | English meaning - Cambridge Dictionary
INCUMBENT definition: 1. officially having the named position: 2. to be necessary for someone: 3. the person who has or….
AD HOC | English meaning - Cambridge Dictionary
AD HOC definition: 1. made or happening only for a particular purpose or need, not planned before it happens: 2. made….
LEVERAGE | English meaning - Cambridge Dictionary
LEVERAGE definition: 1. the action or advantage of using a lever: 2. power to influence people and get the results you….
ENTREPRENEUR | English meaning - Cambridge Dictionary
ENTREPRENEUR definition: 1. someone who starts their own business, especially when this involves seeing a new opportunity….
CULTIVATE | English meaning - Cambridge Dictionary
CULTIVATE definition: 1. to prepare land and grow crops on it, or to grow a particular crop: 2. to try to develop and….
EQUITY | English meaning - Cambridge Dictionary
EQUITY definition: 1. the value of a company, divided into many equal parts owned by the shareholders, or one of the….
LIAISE | English meaning - Cambridge Dictionary
LIAISE definition: 1. to speak to people in other organizations, etc. in order to work with them or exchange….
Business Continuity Plan Pharmaceutical Industry Pd…
Business Continuity Plan Pharmaceutical Industry Pdf: ... Business continuity management …
SMC usiness Continuity lan - SMC株式会社
amongst other companies in the our industry. We promise to do our utmost to fulfill our main responsibility; to …
Business Continuity Plan Pharmaceutical Industry (b…
Business Continuity Plan Pharmaceutical Industry : Business Continuity and Disaster Recovery for …
Business Continuity Plan Pharmaceutical Industry (b…
Business Continuity Plan Pharmaceutical Industry Clifford Lane. Business Continuity Plan …
Crisis Planning for pharmacovigilance complia…
current crisis situation need to be focused on patient care. Therefore, industry aims to minimize any non …
Healthcare Business Continuity Management an…
a BCP. A BCP is a strategic plan that positions an organization’s high-risk business processes to be able to …
MANUFACTURING DISASTER RECOVERY PLAN - Smartsh…
5. IT BUSINESS CONTINUITY STRATEGY The details and necessary information involved in maintaining IT operations …
Business Continuity and Disaster Recovery Workboo…
The Chamber of Commerce and Industry of Western Australia would like to acknowledge the support of the Office …
Business Continuity Plan - Ready.gov
Defne the scope, objectives, and assumptions of the business continuity plan. Business Continuity …
Building Effective Business Development in Pharma - B…
with the fast pace of business development decision making. To address these challenges, we recom …
PLANNING (BCP) CONTINUITY BUSINESS - S…
the Business Continuity Plan (BCP) to mitigate risks and maintain operations. After identifying the risks predicts the …
Business Continuity Plan Pharmaceutical Industry Co…
Business Continuity Plan Pharmaceutical Industry R Bogdan. Business Continuity Plan …
What is BCDR? Business Continuity and Disaster Rec…
Business continuity (BC) and disaster recovery (DR) are closely related practices that support an …
The Professional Practices for Business Continuity Ma…
1. Establish the need for a business continuity program. 2. Obtain support and funding for the business …
NHS Greater Glasgow and Clyde Community Pharmac…
A business continuity plan (BCP) is a documented set of procedures and information intended to deliver …
SADC PHARMACEUTICAL BUSINESS PLAN 2007-201…
pharmaceutical products including African Traditional Medicines that are relevant to local health problems. The …
Business Continuity Planning Booklet - FDIC
The objectives of a business continuity plan (BCP) are to minimize financial loss to the institution; continue to serve …
Guide to Business Continuity and Recovery Planning
A business continuity plan helps you minimize the impact on your business operations regardless of the incident …
BUSINESS CONTINUITY MANAGEMENT - Airmic
Business Continuity Institute Founded in 1994, the BCI defined a set of practices for individuals to be able to …
Good Practice Guidelines - the BCI
Good Practice in Business Continuity. The business continuity (BC) profession continues to evolve as its value is …
Pharmacovigilance (PV) Outsourcing — Emerging P…
media and industry sponsored websites As a result of these regulatory changes, new PV operating models must focus …
SAMPLE Business Continuity Plan - Pennsylvania Associ…
Mar 6, 2020 · and business resumption operations based upon pre-defined time frames. A Business Continuity Plan is …
BUSINESS CONTINUITY PLANNING
Business Continuity Plan amidst COVID-19 - a documented procedure that guides an organization to respond, …
PDG DSCSA and Business Continuity Statement - Draf…
Microsoft Word - PDG DSCSA and Business Continuity Statement - Draft v10 Author: ccoppage Created Date: …
Business Continuity Planning Booklet - FDIC
The objectives of a business continuity plan (BCP) are to minimize financial loss to the institution; continue to serve …
chapter 19 Quality assurance for pharmaceuticals
The purpose of quality assurance in pharmaceutical sup-ply systems is to help ensure that each medicine …
Punjab State Power Corporation Limited (PSPCL…
The Business Continuity Plan (BCP) must protect the assets of the PSPCL and its consumers and provide the …
Business Continuity Management - KPMG
Business continuity plan is unsound, Insufficiency exercise Business impact analysis lacks standardization, Doubt …
Business Continuity Management Standard and …
• Set up effective business continuity plan for delivering main / essential services when an emergency occurs …
Business Continuity Management & the BC Plan…
BUSINESS CONTINUITY PLAN Functional Role Name Designation Date Signature Prepared by Reviewed by Approved by …
7 Steps to Create a Business Continuity Plan - ECI
There are also self-imposed industry standards and expectations that come from external stakeholders including: …
Disaster Recovery and Business Continuity Plans
Business Continuity Plan can make the difference between a temporary business interruption and the …
INTERNATIONAL ISO STANDARD 22301
8.4 Business continuity plans and procedures ... and industry requirements, products and services provided, …
PHARMA 2.0 BUSINESS PLAN - CORE
2: INDUSTRY Pharma 2.0 spans two business environments. The first is the pharmaceutical / biotech industry, the …
EMA pharmacovigilance system manual 12 - Europe…
* BCP = Business continuity plan, IMP = incident management plan. ** RoP = rules of procedure. The …
Business Continuity Plan (BCP) - HDFC Bank
Business Continuity Plan (BCP) ... The Bank has adopted industry leading best practices in establishing a set of …
FDA Emergency Operations Plan Version 3
Dec 4, 2020 · U.S. Food and Drug Administration provides guidance and resources for maintaining business …
Can You Write Off Entire Vehicle Purchase For Busin…
Can You Write Off Entire Vehicle Purchase For Business Distinguishing Credible Sources 13. Promoting …
Sun Pharmaceutical Industries Limited (SPIL)
• Business Continuity Plan • Ensure that appropriate methodology, process and systems are in place to monitor and …
Good Practice Guidelines Edition 7 - the BCI
Highlights of the global guide to good practice in business continuity Business Continuity Management Systems …
Build a Business Continuity Plan
components of the plan to ensure your business remains resilient despite a disaster or disruption. Fill out the …
Business continuity planning at central banks during and …
2 Business continuity planning at central banks during and after the pandemic Executive summary Business …
BUSINESS CONTINUITY MANAGEMENT STANDARD …
7.1 Business Continuity Plans 7.1.1 Each plan must be drawn up using the template found on the Force BC …
Developing a Business Continuity Plan (BCP) - Min…
Developing a Business Continuity Plan (BCP) June 2019 Stay Alert, Stay United and Stay Strong. Be part of the …
Guide to using the business continuity plan template
business owners create a simple business continuity . plan to: • identify risks to your business • plan how to …
NHS England Business Continuity Management To…
• Provided five new business continuity case studies that have been added to the existing case studies (Part 5). • …
Business Continuity Plan Template - EVAC Cardiff
Business continuity management sets out a framework and a process to enable you to plan the delivery of your …
chapter 38 Planning for pharmaceutical management
Why plan? It is always possible to find reasons not to plan: “We’re too busy; we have no time for planning” “. We have …
Continuity of Operations Plan Template and Instructi…
The [Organization Name]’s mission is to [enter mission statement].To accomplish this mission, …
